124 related articles for article (PubMed ID: 37871826)
1. Anti-smoking drugs cytisine and varenicline reduce cardiac reperfusion injury in rat model of myocardial ischemia.
Shaykhutdinova ER; Severyukhina MS; Kholoshenko IV; Gondarenko EA; Shelukhina IV; Kryukova EV; Ismailova AM; Sadovnikova ES; Dyachenko IA; Murashev AN; Tsetlin VI; Utkin YN
Biochimie; 2024 Jan; 216():108-119. PubMed ID: 37871826
[TBL] [Abstract][Full Text] [Related]
2. The contribution of α4β2 and non-α4β2 nicotinic acetylcholine receptors to the discriminative stimulus effects of nicotine and varenicline in mice.
de Moura FB; McMahon LR
Psychopharmacology (Berl); 2017 Mar; 234(5):781-792. PubMed ID: 28028600
[TBL] [Abstract][Full Text] [Related]
3. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
Rollema H; Hurst RS
Psychopharmacology (Berl); 2018 Sep; 235(9):2479-2505. PubMed ID: 29980822
[TBL] [Abstract][Full Text] [Related]
4. Procognitive effects of varenicline in the animal model of schizophrenia depend on α4β2- and α 7-nicotinic acetylcholine receptors.
Potasiewicz A; Golebiowska J; Popik P; Nikiforuk A
J Psychopharmacol; 2018 Dec; 33(1):269881118812097. PubMed ID: 30501536
[TBL] [Abstract][Full Text] [Related]
5. Diverse strategies targeting α7 homomeric and α6β2* heteromeric nicotinic acetylcholine receptors for smoking cessation.
Brunzell DH; McIntosh JM; Papke RL
Ann N Y Acad Sci; 2014 Oct; 1327(1):27-45. PubMed ID: 24730978
[TBL] [Abstract][Full Text] [Related]
6. Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists.
Papke RL; Trocmé-Thibierge C; Guendisch D; Al Rubaiy SA; Bloom SA
J Pharmacol Exp Ther; 2011 May; 337(2):367-79. PubMed ID: 21285282
[TBL] [Abstract][Full Text] [Related]
7. Differential modulation of brain nicotinic acetylcholine receptor function by cytisine, varenicline, and two novel bispidine compounds: emergent properties of a hybrid molecule.
Peng C; Stokes C; Mineur YS; Picciotto MR; Tian C; Eibl C; Tomassoli I; Guendisch D; Papke RL
J Pharmacol Exp Ther; 2013 Nov; 347(2):424-37. PubMed ID: 23959137
[TBL] [Abstract][Full Text] [Related]
8. The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: differences in α4β2 nicotinic receptor activation.
Cunningham CS; McMahon LR
Eur J Pharmacol; 2011 Mar; 654(1):47-52. PubMed ID: 21172344
[TBL] [Abstract][Full Text] [Related]
9. Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys.
Withey SL; Doyle MR; Bergman J; Desai RI
J Pharmacol Exp Ther; 2018 Aug; 366(2):397-409. PubMed ID: 29784663
[TBL] [Abstract][Full Text] [Related]
10. Varenicline blocks β2*-nAChR-mediated response and activates β4*-nAChR-mediated responses in mice in vivo.
Ortiz NC; O'Neill HC; Marks MJ; Grady SR
Nicotine Tob Res; 2012 Jun; 14(6):711-9. PubMed ID: 22241831
[TBL] [Abstract][Full Text] [Related]
11. CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation.
Sala M; Braida D; Pucci L; Manfredi I; Marks MJ; Wageman CR; Grady SR; Loi B; Fucile S; Fasoli F; Zoli M; Tasso B; Sparatore F; Clementi F; Gotti C
Br J Pharmacol; 2013 Feb; 168(4):835-49. PubMed ID: 22957729
[TBL] [Abstract][Full Text] [Related]
12. Chronic treatment with varenicline changes expression of four nAChR binding sites in mice.
Marks MJ; O'Neill HC; Wynalda-Camozzi KM; Ortiz NC; Simmons EE; Short CA; Butt CM; McIntosh JM; Grady SR
Neuropharmacology; 2015 Dec; 99():142-55. PubMed ID: 26192545
[TBL] [Abstract][Full Text] [Related]
13. Differential antagonism and tolerance/cross-tolerance among nicotinic acetylcholine receptor agonists: scheduled-controlled responding and hypothermia in C57BL/6J mice.
de Moura FB; McMahon LR
Behav Pharmacol; 2016 Apr; 27(2-3 Spec Issue):240-8. PubMed ID: 26910582
[TBL] [Abstract][Full Text] [Related]
14. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.
Rollema H; Shrikhande A; Ward KM; Tingley FD; Coe JW; O'Neill BT; Tseng E; Wang EQ; Mather RJ; Hurst RS; Williams KE; de Vries M; Cremers T; Bertrand S; Bertrand D
Br J Pharmacol; 2010 May; 160(2):334-45. PubMed ID: 20331614
[TBL] [Abstract][Full Text] [Related]
15. Distinctive nicotinic acetylcholine receptor functional phenotypes of rat ventral tegmental area dopaminergic neurons.
Yang K; Hu J; Lucero L; Liu Q; Zheng C; Zhen X; Jin G; Lukas RJ; Wu J
J Physiol; 2009 Jan; 587(2):345-61. PubMed ID: 19047205
[TBL] [Abstract][Full Text] [Related]
16. Nicotinic receptor subtypes in rat subfornical organ neurons and glial cells.
Ono K; Toyono T; Inenaga K
Neuroscience; 2008 Jun; 154(3):994-1001. PubMed ID: 18495354
[TBL] [Abstract][Full Text] [Related]
17. A role for α4(non-α6)* nicotinic acetylcholine receptors in motor behavior.
Soll LG; Grady SR; Salminen O; Marks MJ; Tapper AR
Neuropharmacology; 2013 Oct; 73():19-30. PubMed ID: 23688922
[TBL] [Abstract][Full Text] [Related]
18. Use of an α3β4 nicotinic acetylcholine receptor subunit concatamer to characterize ganglionic receptor subtypes with specific subunit composition reveals species-specific pharmacologic properties.
Stokes C; Papke RL
Neuropharmacology; 2012 Sep; 63(4):538-46. PubMed ID: 22580377
[TBL] [Abstract][Full Text] [Related]
19. Nicotinic acetylcholine receptors containing the α4 subunit are critical for the nicotine-induced reduction of acute voluntary ethanol consumption.
Hendrickson LM; Gardner P; Tapper AR
Channels (Austin); 2011; 5(2):124-7. PubMed ID: 21239887
[TBL] [Abstract][Full Text] [Related]
20. Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats.
Maggio SE; Saunders MA; Baxter TA; Nixon K; Prendergast MA; Zheng G; Crooks P; Dwoskin LP; Slack RD; Newman AH; Bell RL; Bardo MT
Psychopharmacology (Berl); 2018 May; 235(5):1439-1453. PubMed ID: 29455292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
